MIAMI
BEACH, Fla., July 30,
2024 /PRNewswire/ -- Immorta Bio Inc, a scientific
longevity company dedicated to "Treating Diseases of Aging and
Treating Aging as Disease™" announced today the appointment of Dr.
Russel Kaufman to the Company's
Board of Directors.
Dr. Russel Kaufman is a venture
partner at Pappas Capital, as well as President Emeritus of The
Wistar Institute, the nation's revered first independent
institution devoted to medical research. Prior to Wistar, Dr.
Kaufman was associated with Duke
University, for over 25 years, with multiple professional
and administrative appointments, including Professor of Medicine,
Chief, Division of Medical Oncology and Transplantation, Dean of
School of Medicine, among others. He is considered a Key Opinion
Leader in the areas of Translational Oncology, Stem Cells, and
Genomics.
"I had the privilege of serving on the board of Dr. Reznik's
successful previous company, Biorasi, and I am honored to
collaborate with him and his team on this exciting new venture,
Immorta Bio," said Dr. Russel
Kaufman. "Having witnessed Dr. Reznik's perseverance,
talent, and executive expertise in translational medicine and
clinical trials, I am confident in the potential of this new
endeavor. The company's focus on longevity, combined with its
cutting-edge technologies in cellular rejuvenation and senolytic
immunotherapy, makes this undertaking particularly exciting.
I am very impressed by the rapid progress the company has made,
advancing from formation to IND filing with the FDA in just one
year. While such accelerated growth is exceptional, it is
characteristic of Dr. Reznik's leadership and the remarkable teams
he leads."
"In our past years of working together, Dr. Kaufman has provided
extremely valuable inputs in the areas of science, medicine and
business. Having someone on our board who excels in all three
disciplines and navigates seamlessly across them is a major
privilege," said Dr. Boris Reznik.
"As we are advancing our therapeutic platforms into the clinic, we
believe Dr. Kaufman's experience, guidance and leadership will
strongly position Immorta Bio to rapidly translate our technologies
into lifesaving medicines."
Dr. Kaufman represents an ideal combination of scientific and
business expertise. He has significantly influenced and
shaped policy at prestigious institutions such as the National
Institutes of Health, the American Cancer Society, and the National
Academy of Sciences. His corporate experience includes board roles
at the CEO Council for Growth in Philadelphia, BioAdvance, Osage Ventures,
Militia Hill Ventures, Biorasi, Neuland Pharmaceutical Labs, and
Credit Suisse (SAB). Additionally, Dr. Kaufman has published over
100 scientific reports and his work has garnered more than 2,000
citations.
About Immorta Bio
Immorta Bio is a longevity-focused biotechnology company
developing efficient and practical personalized cellular
therapeutic platforms focused on Treating Diseases of Aging and
Treating Aging as Disease™. Our therapeutic candidates target unmet
need indications across various organ systems. By developing
personalized cellular therapies for aging-related diseases, we have
the potential to significantly extend our patients' healthy
longevity.
For more information, please visit the Immorta Bio website
at https://www.immortabio.com or find them on X
at https://twitter.com/ImmortaBio.
Company Contact
Dr. Boris Reznik
Immorta Bio
https://www.immortabio.com
+1 305-632-2939
@immortabio
Media Contact
David Schull
Russo Partners, LLC
381069@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dr-russel-kaufman-renowned-medical-innovator-and-business-leader-joins-immorta-bios-board-of-directors-302209872.html
SOURCE Immorta Bio, Inc.